Institutional shares held 145 Million
916K calls
552K puts
Total value of holdings $6.1B
$38.4M calls
$23.2M puts
Market Cap $5.98B
141,940,992 Shares Out.
Institutional ownership 102.45%
# of Institutions 403


Latest Institutional Activity in IONS

Top Purchases

Q2 2025
Assenagon Asset Management S.A. Shares Held: 17.7K ($744K)
Q2 2025
Sonora Investment Management Group, LLC Shares Held: 163K ($6.88M)
Q2 2025
Davenport & CO LLC Shares Held: 64.8K ($2.73M)
Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 7.92K ($334K)
Q2 2025
Exchange Traded Concepts, LLC Shares Held: 8.8K ($371K)

Top Sells

Q2 2025
Abrdn PLC Shares Held: 407K ($17.1M)
Q2 2025
Sovran Advisors, LLC Shares Held: 322K ($13.6M)
Q2 2025
Fifth Third Bancorp Shares Held: 7.6K ($320K)
Q2 2025
Blair William & CO Shares Held: 37.9K ($1.6M)
Q2 2025
Sicart Associates LLC Shares Held: 185K ($7.81M)

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.


Insider Transactions at IONS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
360K Shares
From 33 Insiders
Exercise of conversion of derivative security 288K shares
Open market or private purchase 20K shares
Grant, award, or other acquisition 48.5K shares
Other acquisition or disposition 3.15K shares
Sell / Disposition
193K Shares
From 12 Insiders
Open market or private sale 193K shares

Track Institutional and Insider Activities on IONS

Follow IONIS PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IONS shares.

Notify only if

Insider Trading

Get notified when an Ionis Pharmaceuticals Inc insider buys or sells IONS shares.

Notify only if

News

Receive news related to IONIS PHARMACEUTICALS INC

Track Activities on IONS